WuXi Biologics FY26 H1 net profit rises 5.8% to RMB 2.92 billion; revenue increases 18.4% to RMB 11.79 billion

• Wuxi Biologics posted revenue of RMB 11.79 billion, up 18.4% year-on-year, in the six months ended June 30, 2026.
• Net profit rose 5.8% to RMB 2.92 billion; diluted EPS increased 5.5% to RMB 0.58.
• Gross profit climbed 28.1% to RMB 5.45 billion; gross margin widened 3.5 percentage points to 46.2%.
• Adjusted EBITDA (non-IFRS) increased to RMB 5.38 billion from RMB 4.31 billion; adjusted EBITDA margin expanded to 45.6% from 43.3%.
• Backlog reached US$25.1 billion; integrated projects totaled 1,064, with late-phase projects at 78 and commercial manufacturing at 28.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260825-12298106), on August 25, 2026, and is solely responsible for the information contained therein.